09 September 2021: Calypso Biotech announces first patient with Celiac Disease dosed in anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 Phase 1b Trial, and extension of Series A to €28M Posted at h in Press release by calypsobiotech Click to see full press release
